Background The development of complement inhibitors has greatly improved the outcome of
patients with atypical hemolytic uremic syndrome (aHUS), making kidney transplantation a …

Atypical hemolytic uremic syndrome (aHUS), also called complement-mediated hemolytic
uremic syndrome (CM-HUS), is a rare disease caused by dysregulation in the alternative …

Background Factor H-related protein 5 (FHR-5) is a member of the complement Factor H
protein family. Due to the homology to Factor H, the main complement regulator of the …

Complement factor I (FI) is a central inhibitor of the complement system, and impaired FI
function increases complement activation, contributing to diseases such as age-related …

Background Complement activation in atypical hemolytic uremic syndrome (aHUS), C3
glomerulonephropathy (C3G) and immune complex-mediated membranoproliferative …

Complement factor I (FI) is the nexus for classical, lectin and alternative pathway
complement regulation. FI is an 88kDa plasma protein that circulates in an inactive …

Background: Neutrophil extracellular traps (NETs) can stimulate thrombosis, and their
degradation is decreased in several autoimmune disorders. It was recently reported that …

Background Atypical hemolytic uremic syndrome (aHUS) is characterized by
microangiopathic hemolytic anemia, thrombocytopenia and kidney injury caused by a …

C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) are two rare
diseases caused by dysregulated activity of the alternative pathway of complement …

Background Genetic susceptibility to atypical hemolytic uremic syndrome (aHUS) may lie
within genes regulating or activating the alternate complement and related pathways …